FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955276803> ?p ?o ?g. }

• W2955276803 abstract "With the emergence and growing number of drug-resistant Plasmodium falciparum, a new drug for malaria control must be urgently developed. The new antimalarial synthetic compound N-251 was recently discovered. As an endoperoxide structure in the body, the compound shows high antimalarial activity and curative effects. We performed a pharmacokinetic (PK) analysis of N-251 under various conditions using mice to understand the inhibitory effect of N-251 in parasite-infected mice. PK study of N-251 after intravenous and oral administration in mice showed plasma concentration of N-251 was decreased drastically by intravenous route. Cmax was reached in 2 h after oral administration of N-251, and the level decreased to a level similar to that obtained after intravenous administration. The area under the curves (AUCs) of the plasma concentration of N-251 increased dose-proportionally in both administrations, and bioavailability (F) was approximately 23%. Additionally, Tmax, Cmax, AUC, and F increased in fasted mice compared to normal-fed mice after the administration of N-251, indicating the influence of diet on the absorption kinetics of N-251. Furthermore, in parasite-infected fasted mice, the plasma concentration-time profile of N-251 was similar to that in normal-fasted mice. Based on the PK parameters of single oral administration of N-251, we investigated the effect of multiple oral doses of N-251 (68 mg/kg three times per day for 2 days) in normal-fed mice. The plasma concentration of N-251 was between 10 and 1000 ng/mL. The simulation curve calculated based on the PK parameters obtained from the single-dose study well described the plasma concentrations after multiple oral dosing, indicating that N-251 did not accumulate in the mice. Multiple oral administrations of N-251 in mice were required to completely eliminate parasites without accumulation of N-251. N-251 has been selected as a potent antimalarial candidate. We found that N-251 showed short half-life in plasma, and AUCs increased proportionally to dose. With multiple doses of N-251, the plasma level of N-251 was greater than 10 ng/mL in normal-fed mice, and accumulation of N-251 was not observed; however, multiple treatments with N-251 are required for the complete cure of parasite-infected mice. Determining the appropriate dosage was an important step in the clinical applications of N-251." @default.
• W2955276803 created "2019-07-12" @default.
• W2955276803 creator A5019489630 @default.
• W2955276803 creator A5022162537 @default.
• W2955276803 creator A5033745833 @default.
• W2955276803 creator A5053501652 @default.
• W2955276803 creator A5064234451 @default.
• W2955276803 creator A5069278982 @default.
• W2955276803 creator A5075771709 @default.
• W2955276803 creator A5085916499 @default.
• W2955276803 creator A5088109364 @default.
• W2955276803 date "2019-07-05" @default.
• W2955276803 modified "2023-10-01" @default.
• W2955276803 title "Pharmacokinetic analysis of new synthetic antimalarial N-251" @default.
• W2955276803 cites W1530621923 @default.
• W2955276803 cites W1972693841 @default.
• W2955276803 cites W1990392794 @default.
• W2955276803 cites W1990524106 @default.
• W2955276803 cites W2006156671 @default.
• W2955276803 cites W2009012286 @default.
• W2955276803 cites W2013010118 @default.
• W2955276803 cites W2022563732 @default.
• W2955276803 cites W2038159058 @default.
• W2955276803 cites W2040713555 @default.
• W2955276803 cites W2041794770 @default.
• W2955276803 cites W2044702381 @default.
• W2955276803 cites W2067428749 @default.
• W2955276803 cites W2076029682 @default.
• W2955276803 cites W2087526401 @default.
• W2955276803 cites W2098184601 @default.
• W2955276803 cites W2113717321 @default.
• W2955276803 cites W2135926190 @default.
• W2955276803 cites W2152921443 @default.
• W2955276803 cites W2161311583 @default.
• W2955276803 cites W2171055217 @default.
• W2955276803 doi "https://doi.org/10.1186/s41182-019-0167-4" @default.
• W2955276803 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6611044" @default.
• W2955276803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31312098" @default.
• W2955276803 hasPublicationYear "2019" @default.
• W2955276803 type Work @default.
• W2955276803 sameAs 2955276803 @default.
• W2955276803 citedByCount "3" @default.
• W2955276803 countsByYear W29552768032020 @default.
• W2955276803 countsByYear W29552768032023 @default.
• W2955276803 crossrefType "journal-article" @default.
• W2955276803 hasAuthorship W2955276803A5019489630 @default.
• W2955276803 hasAuthorship W2955276803A5022162537 @default.
• W2955276803 hasAuthorship W2955276803A5033745833 @default.
• W2955276803 hasAuthorship W2955276803A5053501652 @default.
• W2955276803 hasAuthorship W2955276803A5064234451 @default.
• W2955276803 hasAuthorship W2955276803A5069278982 @default.
• W2955276803 hasAuthorship W2955276803A5075771709 @default.
• W2955276803 hasAuthorship W2955276803A5085916499 @default.
• W2955276803 hasAuthorship W2955276803A5088109364 @default.
• W2955276803 hasBestOaLocation W29552768031 @default.
• W2955276803 hasConcept C112705442 @default.
• W2955276803 hasConcept C121332964 @default.
• W2955276803 hasConcept C125287762 @default.
• W2955276803 hasConcept C181389837 @default.
• W2955276803 hasConcept C185592680 @default.
• W2955276803 hasConcept C203014093 @default.
• W2955276803 hasConcept C22979827 @default.
• W2955276803 hasConcept C24890656 @default.
• W2955276803 hasConcept C2777056448 @default.
• W2955276803 hasConcept C2778048844 @default.
• W2955276803 hasConcept C2778371730 @default.
• W2955276803 hasConcept C2987276129 @default.
• W2955276803 hasConcept C3020079912 @default.
• W2955276803 hasConcept C71924100 @default.
• W2955276803 hasConcept C98274493 @default.
• W2955276803 hasConceptScore W2955276803C112705442 @default.
• W2955276803 hasConceptScore W2955276803C121332964 @default.
• W2955276803 hasConceptScore W2955276803C125287762 @default.
• W2955276803 hasConceptScore W2955276803C181389837 @default.
• W2955276803 hasConceptScore W2955276803C185592680 @default.
• W2955276803 hasConceptScore W2955276803C203014093 @default.
• W2955276803 hasConceptScore W2955276803C22979827 @default.
• W2955276803 hasConceptScore W2955276803C24890656 @default.
• W2955276803 hasConceptScore W2955276803C2777056448 @default.
• W2955276803 hasConceptScore W2955276803C2778048844 @default.
• W2955276803 hasConceptScore W2955276803C2778371730 @default.
• W2955276803 hasConceptScore W2955276803C2987276129 @default.
• W2955276803 hasConceptScore W2955276803C3020079912 @default.
• W2955276803 hasConceptScore W2955276803C71924100 @default.
• W2955276803 hasConceptScore W2955276803C98274493 @default.
• W2955276803 hasFunder F4320321945 @default.
• W2955276803 hasFunder F4320324324 @default.
• W2955276803 hasFunder F4320334764 @default.
• W2955276803 hasIssue "1" @default.
• W2955276803 hasLocation W29552768031 @default.
• W2955276803 hasLocation W29552768032 @default.
• W2955276803 hasLocation W29552768033 @default.
• W2955276803 hasLocation W29552768034 @default.
• W2955276803 hasOpenAccess W2955276803 @default.
• W2955276803 hasPrimaryLocation W29552768031 @default.
• W2955276803 hasRelatedWork W1982777678 @default.
• W2955276803 hasRelatedWork W2023029780 @default.
• W2955276803 hasRelatedWork W2035255429 @default.
• W2955276803 hasRelatedWork W2359419803 @default.
• W2955276803 hasRelatedWork W2373237830 @default.

• next